CSE Activators Inhibit Calcium Deposition in Heterotopic Calcification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for heterotopic calcification (HC) are inadequate, as existing therapies fail to effectively prevent or treat HC, leading to pain, tissue degradation, and increased risk of osteoarthritis and tendon rupture, with limited options beyond surgery and NSAIDs, which have significant side effects and recurrence rates.
Innovation Solution
Development of novel small molecule activators of the cystathionine-gamma-lyase enzyme (CSE) to enhance H2S production, which inhibits chondrocyte calcification and IL-6 secretion, thereby addressing hypermineralization-related conditions such as HC and osteoarthritis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If NSAIDs or bisphosphonates are used to reduce pain and severity, then pain management is improved, but they have no effect on HC and do not address the underlying calcification process
Solution Approach 1:
The patent converts the harmful effect of calcium deposition into a beneficial therapeutic target by using compounds that selectively inhibit the calcification process. The small molecule compounds target specific pathways involved in calcium crystal formation and deposition, transforming the approach from symptomatic pain management to disease-modifying therapy that addresses the root cause of HC while potentially reducing pain through prevention of further calcification-induced tissue damage
Solution Approach 2:
The patent introduces small molecule compounds as intermediary substances that mediate between the calcification process and the body's natural regulatory mechanisms. These compounds act as molecular mediators that interfere with the crystallization process, preventing calcium deposits from forming in soft tissues without requiring surgical intervention or having the limitations of existing pharmacological approaches
2Reliability
If radiation therapy is used to interfere with HC formation, then HC prevention is improved, but late-term side effects occur
Solution Approach 1:
The patent employs small molecule compounds that act as temporary, reversible inhibitors of the calcification process. Unlike radiation therapy which causes permanent tissue damage, these compounds provide transient pharmacological intervention that can be administered systemically and eliminated from the body, avoiding cumulative long-term side effects while effectively preventing HC formation during the treatment period
Solution Approach 2:
The patent replaces the mechanical/physical approach of radiation therapy with a chemical/pharmacological approach using small molecule compounds. This substitution allows for more selective targeting of the calcification pathway through molecular recognition and binding, achieving HC prevention through biochemical mechanisms rather than ionizing radiation, thereby eliminating radiation-induced late-term side effects
3Reliability
If surgery is performed to remove already formed HC, then HC removal is improved, but complications frequently occur and radiological recurrence rate is around 80%
Solution Approach 1:
The patent employs small molecule compounds to prevent HC formation in the first place through inhibition of calcium crystal nucleation and growth. By taking preliminary pharmacological action to block the calcification pathway before significant deposits form, the need for subsequent surgical removal is avoided, thereby eliminating surgical complications and preventing the high recurrence rates associated with post-surgical regrowth of calcified tissue
Solution Approach 2:
The patent enables the body's natural systems to prevent and potentially regress HC through pharmacological support of endogenous protective mechanisms. The small molecule compounds work synergistically with the body's own regulatory systems to maintain tissue health and prevent pathological calcification, allowing the physiological system to 'self-service' by preventing HC formation without requiring external surgical intervention and reducing reliance on invasive procedures with high recurrence rates
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CSE activators effectively reduce calcium deposition and inflammation in musculoskeletal tissues, providing a therapeutic approach to prevent and treat HC and related conditions by enhancing H2S production and improving the anabolic/catabolic balance.
Implementation Method 1
cystathionine-gamma-lyase enzyme (CSE)... three different enzymes generate H2S intracellularly: cystathionine beta-synthase (CBS), cystathionine gamma-lyase (CSE) and 3-mercaptopyruvate sulfurtransferase (3 MST). The enzymes use cysteine as substrate to produce H2S
Data Source
AI summary
The present disclosure relates to novel compounds that are activators of the cystathionine-gamma-lyase enzyme (CSE). The disclosure also relates to methods for preparing the compounds, methods of treatment and/or prevention and to pharmaceutical compositions comprising such compounds.